{"title":"Docking study, Synthesis, Characterization and Preliminary cytotoxic evaluation of new 1,2,3,4-tetrahydroppyrimidine derivatives","authors":"Noor M. Mohammed","doi":"10.22317/jcms.v8i5.1281","DOIUrl":null,"url":null,"abstract":"Objective: This study resolved that1 these anew synthesized analogs1 may 1be embodied as1 an 1exploitable foundation of new 1anticancer1 1agents to competition breast 1cancer \nMethods: By means of The crystal1 structure of Histone deacetylases (HDACs-8) with Vorinostat (SAHA) as 1a co-crystalized1 ligand 1was gained1 from 1the protein 1data-bank 1 (PDB 1code 4QA0) as a result 1of 1docking the compounds (V a,s, V b,s, V a,t and V b,t) give 1good docking 1scores compared1 to the standard. 1 Compounds (V a,s, V b,s, V a,t and V b,t) was synthesized1 by multistep procedures1 from the reaction of intermediate derivatives (IV a,b) and the thiosemicarbazide or semicarbazide . The chemical1 structures1 of the1 target compounds11 and 1their intermediates1 were1 confirmed by 1FT-IR and1H 1NMR \nResults: The in-vitro cytotoxicity1 assay (MTT assay) demonstrated1 that compounds1 V a,t and V b,t showed1 good inhibition 1ratios in Breast1 cancer cell line1 (MCF-7) and human colon adenocarcinoma (HRT-18) 1comparable with drug1 control Vorinostat (SAHA). \nConclusion: 1From the docking1 study, it was1 concluded1 that C=S moiety were very1 1successful to bind 1tightly to the zinc binding group of HDAC enzyme by making numerous 1interaction modes.","PeriodicalId":42860,"journal":{"name":"Journal of Contemporary Medical Sciences","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22317/jcms.v8i5.1281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study resolved that1 these anew synthesized analogs1 may 1be embodied as1 an 1exploitable foundation of new 1anticancer1 1agents to competition breast 1cancer
Methods: By means of The crystal1 structure of Histone deacetylases (HDACs-8) with Vorinostat (SAHA) as 1a co-crystalized1 ligand 1was gained1 from 1the protein 1data-bank 1 (PDB 1code 4QA0) as a result 1of 1docking the compounds (V a,s, V b,s, V a,t and V b,t) give 1good docking 1scores compared1 to the standard. 1 Compounds (V a,s, V b,s, V a,t and V b,t) was synthesized1 by multistep procedures1 from the reaction of intermediate derivatives (IV a,b) and the thiosemicarbazide or semicarbazide . The chemical1 structures1 of the1 target compounds11 and 1their intermediates1 were1 confirmed by 1FT-IR and1H 1NMR
Results: The in-vitro cytotoxicity1 assay (MTT assay) demonstrated1 that compounds1 V a,t and V b,t showed1 good inhibition 1ratios in Breast1 cancer cell line1 (MCF-7) and human colon adenocarcinoma (HRT-18) 1comparable with drug1 control Vorinostat (SAHA).
Conclusion: 1From the docking1 study, it was1 concluded1 that C=S moiety were very1 1successful to bind 1tightly to the zinc binding group of HDAC enzyme by making numerous 1interaction modes.
目的:本研究确定了这些新合成的类似物可作为新的抗癌药物与乳腺癌竞争的开发基础。方法:利用组蛋白去乙酰化酶(hdac -8)与伏立诺他(SAHA)共结晶的晶体结构,从蛋白数据库1 (pdb1编码4QA0)中获得共结晶配体1,对接化合物(V a,s, V b,s, V a,t和V b,t)获得较好的对接分数。由中间衍生物(iva,b)与氨基脲或氨基脲通过多步反应合成了化合物(va,s, vb,s, va,t和vb,t)。结果:体外细胞毒性试验(MTT)表明,化合物1 V a,t和V b,t对乳腺癌细胞系(MCF-7)和人结肠腺癌(HRT-18)具有良好的抑制作用,与对照药物伏立诺他(SAHA)相当。结论:从对接研究中可以得出,C=S片段通过多种相互作用模式,非常成功地与HDAC酶的锌结合基团紧密结合。